This approach presents a promising strategy for addressing hypoxia-driven treatment resistance in pancreatic cancer by downregulating HIF-1α, a key regulator of tumor survival under low oxygen conditions. The gene discussed is HIF1A; the disease is familial pancreatic carcinoma.